<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">28844318</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>03</Month>            <Day>02</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>03</Month>            <Day>02</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1879-114X</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>39</Volume>                    <Issue>9</Issue>                    <PubDate>                        <Year>2017</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>Clinical therapeutics</Title>                <ISOAbbreviation>Clin Ther</ISOAbbreviation>            </Journal>            <ArticleTitle>Tolerability of the SQ Tree SLIT Tablet in Adults.</ArticleTitle>            <Pagination>                <MedlinePgn>1858-1867</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0149-2918(17)30874-3</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clinthera.2017.08.003</ELocationID>            <Abstract>                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The tree pollen sublingual immunotherapy (SLIT)-tablet (ALK, Denmark) is being developed for the treatment of tree pollen induced allergic rhinitis with or without conjunctivitis. The objective of this Phase I trial was to investigate the tolerability and acceptable dose range of the SQ tree SLIT-tablet in adults with allergic rhinoconjunctivitis.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">The trial was a randomized, double-blind, placebo-controlled, dose escalation Phase I trial that included 70 adults (aged 19-61 years) with birch pollen-induced rhinoconjunctivitis with or without mild to moderate asthma. The trial included 6 different dosage groups that were randomized 3:1 to active treatment or placebo once daily for 28 days. Adverse events (AEs) were coded in the Medical Dictionary for Regulatory Activities by medically qualified personnel. Immunologic assessments included IgE and IgE-blocking factor.</AbstractText>                <AbstractText Label="FINDINGS" NlmCategory="RESULTS">Most (96%) reported AEs were mild, and only 5 severe events (0.2%) were reported. The most frequently reported investigational medicinal product-related AEs were oral pruritus, ear pruritus, mouth edema, sensation of foreign body, throat irritation, pharyngolaryngeal pain, dry throat, tongue blistering, eye pruritus, and headache. The trial included doses ranging from 1 to 24 development units (DU), and the mean number of investigational medicinal product-related AEs per participant was highest in the 24 DU group. The 12 and 24 DU doses induced statistically significant changes from baseline compared with placebo in birch specific IgE and IgE-blocking factor.</AbstractText>                <AbstractText Label="IMPLICATIONS" NlmCategory="CONCLUSIONS">The trial found that doses up to 12 DU of the SQ tree SLIT tablet have a tolerability profile suitable for at-home administration. An immunomodulatory effect was found for all doses included in the trial, and doses up to 12 DU were thus chosen for further clinical development of the SQ tree SLIT tablet. EudraCT identifier: 2007-003234-42.</AbstractText>                <CopyrightInformation>Copyright © 2017 Elsevier HS Journals, Inc. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Birk</LastName>                    <ForeName>Anne O</ForeName>                    <Initials>AO</Initials>                    <AffiliationInfo>                        <Affiliation>Global Pharmacovigilance and Clinical Development, ALK, Hørsholm, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Andersen</LastName>                    <ForeName>Jens S</ForeName>                    <Initials>JS</Initials>                    <AffiliationInfo>                        <Affiliation>Global Pharmacovigilance and Clinical Development, ALK, Hørsholm, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Villesen</LastName>                    <ForeName>Hanne H</ForeName>                    <Initials>HH</Initials>                    <AffiliationInfo>                        <Affiliation>Global Pharmacovigilance and Clinical Development, ALK, Hørsholm, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Steffensen</LastName>                    <ForeName>Maria A</ForeName>                    <Initials>MA</Initials>                    <AffiliationInfo>                        <Affiliation>Global Pharmacovigilance and Clinical Development, ALK, Hørsholm, Denmark. Electronic address: mafdk@alk.net.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Calderon</LastName>                    <ForeName>Moises A</ForeName>                    <Initials>MA</Initials>                    <AffiliationInfo>                        <Affiliation>Imperial College London, National Heart and Lung Institute, Royal Brompton Hospital, London, England.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2017</Year>                <Month>08</Month>                <Day>23</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Clin Ther</MedlineTA>            <NlmUniqueID>7706726</NlmUniqueID>            <ISSNLinking>0149-2918</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000485">Allergens</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000951">Antigens, Neoplasm</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D013607">Tablets</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C020163">blocking factor</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>37341-29-0</RegistryNumber>                <NameOfSubstance UI="D007073">Immunoglobulin E</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000286" MajorTopicYN="N">Administration, Sublingual</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000485" MajorTopicYN="N">Allergens</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000951" MajorTopicYN="N">Antigens, Neoplasm</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001249" MajorTopicYN="N">Asthma</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D003233" MajorTopicYN="N">Conjunctivitis, Allergic</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D003718" MajorTopicYN="N">Denmark</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D007073" MajorTopicYN="N">Immunoglobulin E</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011058" MajorTopicYN="N">Pollen</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006255" MajorTopicYN="N">Rhinitis, Allergic, Seasonal</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D063729" MajorTopicYN="Y">Sublingual Immunotherapy</DescriptorName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D013607" MajorTopicYN="N">Tablets</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014197" MajorTopicYN="N">Trees</DescriptorName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">allergic rhinoconjunctivitis</Keyword>            <Keyword MajorTopicYN="N">allergy immunotherapy</Keyword>            <Keyword MajorTopicYN="N">birch pollen</Keyword>            <Keyword MajorTopicYN="N">immunology</Keyword>            <Keyword MajorTopicYN="N">sublingual immunotherapy tablet</Keyword>            <Keyword MajorTopicYN="N">tolerability</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>05</Month>                <Day>19</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2017</Year>                <Month>07</Month>                <Day>03</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2017</Year>                <Month>08</Month>                <Day>02</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2017</Year>                <Month>8</Month>                <Day>29</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>3</Month>                <Day>3</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2017</Year>                <Month>8</Month>                <Day>29</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">28844318</ArticleId>            <ArticleId IdType="pii">S0149-2918(17)30874-3</ArticleId>            <ArticleId IdType="doi">10.1016/j.clinthera.2017.08.003</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>